 phase II study combined methotrexate teniposide infusions reinduction therapy relapsed childhood acute lymphoblastic leukemia Pediatric Oncology Group study Teniposide intracellular methotrexate MTX polyglutamate derivatives vitro potential therapeutic index regimens MTX phase II study children adolescents acute lymphoblastic leukemia first second marrow relapse simultaneous sequential continuous infusions MTX reinduction Infusions hours completion MTX infusion sequential group Dosages plasma concentration levels microns MTX microns total infusion times hours Significant toxicity first patients scheduled infusion drug-related death reduction infusion duration reduced dose similar manageable toxicity Examination bone marrow days therapy complete partial marrow remissions fourth patient aplastic marrow day chemotherapy complete remission CR day obvious clinical advantage infusion schedule small sample sizes definitive conclusions response rate therapeutic window patients refractory disease need investigation alternative schedules concomitant therapy drug combination